Pearson: Molecular structure of C10H14O called 'sex, drugs and rock n roll'. Oregano, rosemary and thyme, saffron all the same #Tricon
1:15pm February 24th 2017 via Hootsuite
Pearson: Same year 1865 knew and classified molecules; non-additive properties; nicotine was already char, toxicologically tracked. #Tricon
1:13pm February 24th 2017 via Hootsuite
Pearson: Explained the periodic table as a helix. 1865 had 56 elements, properties key to understanding the world (and tinker w/it) #Tricon
1:12pm February 24th 2017 via Hootsuite
Pearson: What would a TED talk be in 1865? Dodgson, Drawin, Mendel, de Chancourtois? The Telluric Helix #Tricon
1:11pm February 24th 2017 via Hootsuite
Pearson:Alice in Wonderland: a bottle saying 'Drink Me', 'contains carbon, hydrogen, nitrogen, oxygen' *may be hazardous (VUS) #Tricon
1:10pm February 24th 2017 via Hootsuite
Pearson: Shows a bottle with 'READ ME' label, ~6.6GB, and a long scroll inside. His own genome has ABCG2 R236X - carrier in AshJ #Tricon
1:09pm February 24th 2017 via Hootsuite
Pearson: Introduced as 'always interesting, always provocative' (yes that's him) #Tricon
1:07pm February 24th 2017 via Hootsuite
.@genomenathan Nathaniel Pearson (NY Genome Ctr NY) Mendel, meet Mendeleev. Why genotypes matter... and what you can do about it #Tricon
Mack: Showed interesting OS curves in panc ca separating out on KRAS status in ctDNA https://t.co/xYomOrJfFo #Tricon
12:58pm February 24th 2017 via Hootsuite
Mack: Can ctDNA ID resistance mechanisms? Fig from '14 rev https://t.co/zSWqyYVfER #Tricon
12:52pm February 24th 2017 via Hootsuite
Mack: Dist. of ctDNA alterations in ctDNA; MET ex14skip at 0.4%;MET ampl 5.7%; ERBB2 amp 4.4%; ROS1 fus 0.2%; ALK 1.3%; RET 0.9% #Tricon
12:49pm February 24th 2017 via Hootsuite
Mack: One exception in plasma was EGFR T790M, seen in plasma but not in TCGA due to pre-trtmt specimens #Tricon
12:47pm February 24th 2017 via Hootsuite
Mack: Showed evolution in KRAS, PIK3CA, between plasma and tissue over time. Exact same freq's #Tricon
12:46pm February 24th 2017 via Hootsuite
Mack: Liquid biopsy mut detection rates across tissue types: lung ca was 85%. Plasma ctDNA found truncal changes at TCGA freq's #Tricon
12:45pm February 24th 2017 via Hootsuite
Mack: Collaborating with Guardant, reported 8.3K NSCLC cases, cp to TCGA, showed mutual exclusivity of driver oncogenes #Tricon
12:44pm February 24th 2017 via Hootsuite
Mack: Another example, MET ex14skip as a driver. crizotinib in NSCLC; 10/15 pts with Complete Response. #Tricon
12:43pm February 24th 2017 via Hootsuite
Mack: For ROS1 and crizotinib, ORR 72%, physicans like to see this. #Tricon
12:42pm February 24th 2017 via Hootsuite
Mack: But largely adopted ones only are about a total of 22%; EGFR 14%, ERBB2 2%, fusions at 6% #Tricon
12:41pm February 24th 2017 via Hootsuite
Mack: ccfDNA stable for a few hours; already used in clinical practice. Shows pie chart of actionable lung ca drivers #Tricon
12:40pm February 24th 2017 via Hootsuite
Philip Mack (UC Davis CA) Are liquid biopsies ready for routine clinical use? #Tricon
12:37pm February 24th 2017 via Hootsuite
Febbo: Reimbursement w/evidence generation provide access to valid tests for pts, while generating data to support utility #Tricon
12:36pm February 24th 2017 via Hootsuite
(Febbo: Looking at the graph, its up to $207K per life year gained in 13.) #Tricon
12:35pm February 24th 2017 via Hootsuite
Febbo: Shows this fascinating graphic #Tricon https://t.co/33wPwMjojQ And here's a PDF https://t.co/WpJR8zygJk Price per year of life gained
12:34pm February 24th 2017 via Hootsuite
Febbo: For the healthcare provider, much more worried about the cost of the Rx, rather than the cost of the test #Tricon
12:31pm February 24th 2017 via Hootsuite
Febbo: The cost assoc'd with the test is such a small proportion: high expectations of pts unmet, toxicity #Tricon
Febbo: 17 genes in OncotypeSEQ Liquid Select; but population data needs to be imported back to inform decisions. #Tricon
12:30pm February 24th 2017 via Hootsuite
(NB: Dr. Febbo is an excellent, top-rate presenter. Excellent illustrations, very clear, high-density content. Kudos!) #Tricon
12:29pm February 24th 2017 via Hootsuite
Febbo: And the FDA is open to this; points to this FDA PDF https://t.co/erz38zvnEL as the model for oncology #Tricon
12:28pm February 24th 2017 via Hootsuite
Febbo: No single institution will develop enough. They have tested 600K pts with OncotypeDx. They have access to SEER, 38K pts' data #Tricon
12:26pm February 24th 2017 via Hootsuite
Febbo: Data sharing will be required; many 10's of thousands of tests administered by academia and companies #Tricon
Febbo: And the result? 250 pts total for the trial (!) Add background genetic context, AF, mut burden, disease context #Tricon
12:25pm February 24th 2017 via Hootsuite
Febbo: 132K pts, 20% of these mCRC, 80% adequate tissue, 8% w/PIC3CA, 30% eligable, 50% consent (all optimistic #'s) #Tricon
12:24pm February 24th 2017 via Hootsuite
Febbo: Need appropriate disease CONTEXT - hypothetical Ph II study of PIK3CA+ in mCRC, goes thru numbers. #Tricon
12:23pm February 24th 2017 via Hootsuite
Febbo: Blood profiling atlas in cancer (Blood PAC) as part of Cancer Moonshot '17 ref https://t.co/wYQePouh3U #Tricon
12:21pm February 24th 2017 via Hootsuite
Febbo: Indep guidelines play a critical role in helping ensure quality. NCCN, ESMO, country-spec ones #Tricon
12:20pm February 24th 2017 via Hootsuite
Febbo: Limitations: quality ("Bob's genome", "ccfDNA R Us") - and influential paper https://t.co/sH5uZdLwYq and FDA LDT response #Tricon
12:19pm February 24th 2017 via Hootsuite
Febbo: BELLE-2 Trial, PIK3CA mutations outperformed in ccfDNA Baselga SABCS abstract, manuscript publ. soon #Tricon
12:15pm February 24th 2017 via Hootsuite
Febbo: Refers to FASTACT2 w/cobas EGFR test; overall hazard ratio almost identical. Wu '13 https://t.co/vA3oEdHlKW #Tricon
Febbo: Overlap between FFPE and ccfDNA in EGFR: 17% to 94%. Bai '09; Kimura '07; Goto '2012; Douillard '14; Kim '13; Couraud '14 #Tricon
12:13pm February 24th 2017 via Hootsuite
Febbo: If base specificity is 99.9%, in 100kb smpl is 100 FP calls; specificity of sample is 0%. At six 9's, 1/100kb <1 FP call #Tricon
12:11pm February 24th 2017 via Hootsuite
Febbo: Specificity impt as well, reported on a per-sample basis (>99%); per variant, much higher: six 9's. #Tricon
12:09pm February 24th 2017 via Hootsuite
Febbo: Analytical spec's: across SNVs, indels, fusions, CNV gains. (2.7 copies at 95% detection rate) #Tricon
Febbo: Are pt outcomes improved, and physician behaviors changed as a result of clinical trials? OncotypeSEQ Liquid Select #Tricon
12:08pm February 24th 2017 via Hootsuite
Febbo: Analytical validity; then clinical validity (concord w/tissue or assoc of ctDNA var to drug benefit; then clinical utility #Tricon
12:07pm February 24th 2017 via Hootsuite
Febbo: 'We have to do a job for them' (Physicians, patients and payers); how liquid biopsy shines. #Tricon
12:06pm February 24th 2017 via Hootsuite
Febbo: Reviews the variety of oncology tests Genomic Health offers (Breast Recurrance, Breast DCIS, AR-V7 etc) and now ccfDNA #Tricon
12:05pm February 24th 2017 via Hootsuite
Febbo: Starts with CML and Gleevec and its importance in cancer treatment and molecular medicine #Tricon
12:04pm February 24th 2017 via Hootsuite
Phillip Febbo (Genomic Health CA) Building evidence of utility for cfDNA in cancer management #Tricon
12:03pm February 24th 2017 via Hootsuite
Kashyap: Showed taxon-taxon correlation stronger in responders; suggests higher colonization resistance #Tricon
12:00pm February 24th 2017 via Hootsuite
Kashyap: Used V4 and QIIME with assignment to OTU; '16 ref https://t.co/hvn5wYhF6n Showed ROC at AUC 0.85 for trtmt response #Tricon
11:59am February 24th 2017 via Hootsuite
